AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36718624
Drug: Senaparib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib (oral, 100 mg daily in 3-week cycles)
Trial: 36718994
Drug: Sham electrodes
RxNorm normalized name: ELECTRODE ELECTROLYTE SPRAY,TOP,PMT#CS4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electrodes as placebo treatments
Trial: 36718994
Drug: Topical gels
RxNorm normalized name: Topicale
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical gels as placebo treatments
Trial: 36719104
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily + metronidazole 400 mg three times daily)
Trial: 36719104
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily)
Trial: 36720083
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg once-daily for 3 years
Trial: 36720090
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa monotherapy
Trial: 36720133
Drug: Efanesoctocog alfa
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efanesoctocog alfa on-demand treatment for 26 weeks followed by prophylaxis for 26 weeks in group B
Trial: 36720570
Drug: FOLFOXIRI (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI (5-fluorouracil, oxaliplatin, and irinotecan) for four cycles as neoadjuvant chemotherapy (NAC)
Trial: 36720576
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg semaglutide once a week
Trial: 36721157
Drug: L-GF injection
RxNorm normalized name: remestemcel-L Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-GF injection
Trial: 36721157
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L-GF and Control)
Trial: 36721920
Drug: 260 IU
RxNorm normalized name: acetaminophen 260 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 260 IU recombinant hCG (rhCG) daily injections for 8 weeks
Trial: 36721963
Drug: Inhaled siR-7-EM/KK-46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled siR-7-EM/KK-46 (3.7 mg/day)
Trial: 36721963
Drug: Inhaled siR-7-EM/KK-46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled siR-7-EM/KK-46 (11.1 mg/day)
Trial: 36721963
Drug: Standard etiotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard etiotropic drug treatment (control group)
Trial: 36722133
Drug: DAAs (direct-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAs (direct-acting antivirals)
Trial: 36722147
Drug: RSVPreF3 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 (60 µg)
Trial: 36722147
Drug: RSVPreF3 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 (120 µg)
Trial: 36723678
Drug: Axi-cabtagene ciloleucel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axi-cabtagene ciloleucel (axi-cel); chimeric antigen receptor T-cell therapy
Trial: 38939456
Drug: Tafamidis (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis (80 mg or 20 mg)
Trial: 36724001
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent or combination therapy (inactive trials)
Trial: 36724001
Drug: SARC006 trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARC006 trial (upfront chemotherapy in chemotherapy naïve patients)
Trial: 36724109
Drug: Zuranolone, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuranolone, dosage and duration not available
Trial: 36724193
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500mg twice daily for 8 weeks
Trial: 36724311
Drug: Usual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual insulin pump (UP)
Trial: 36724311
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin delivery (AID) (MiniMed™ 780G)
Trial: 36724328
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (hypothermia + machine perfusion)
Trial: 36724328
Drug: Hypothermia vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia vs Combination Therapy
Trial: 36724328
Drug: Combination Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Therapy vs Machine Perfusion
Trial: 36724401
Drug: Smartwatch prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartwatch prescription for AF
Trial: 36724434
Drug: Semisuperboosted LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semisuperboosted LPV/r (adding a ritonavir 100 mg crushed tablet)
Trial: 36724434
Drug: Rifampicin co-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin co-treatment
Trial: 36724515
Drug: Olutasidenib (FT-2102)
RxNorm normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olutasidenib (FT-2102) 150 mg twice daily
Trial: 36724759
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF) at a convective rate of 5 µL/min with a maximum volume of infusion of 500 mL
Trial: 36725084
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A)
Trial: 36725084
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A1)
Trial: 36725090
Drug: CDED+antibiotics (azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDED+antibiotics (azithromycin 7.5 mg/kg and metronidazole 20 mg/kg)
Trial: 36725090
Drug: CDED+antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDED+antibiotics
Trial: 36725117
Drug: GPRC5D-targeted CAR
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPRC5D-targeted CAR T cells (OriCAR-017) administered as a single dose of intravenous 1 × 10^6 cells/kg
Trial: 36726737
Drug: Benralizumab 10
RxNorm normalized name: BENRALIZUMAB 10MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 10 mg
Trial: 36726737
Drug: Benralizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (all doses)
Trial: 36727105
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment for 1 year
Trial: 36727222
Drug: Anlotinib in
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib in combination with CAPEOX
Trial: 36727222
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with CAPEOX
Trial: 36727397
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor therapy
Trial: 36727741
Drug: Etoposide plus
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide plus lobaplatin (EL) with concurrent thoracic radiotherapy
Trial: 36727741
Drug: Etoposide plus
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide plus cisplatin (EP) with concurrent thoracic radiotherapy
Trial: 36727868
Drug: Tulobuterol patch
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol patch (1 mg)
Trial: 36728217
Drug: Preemptive antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF)
Trial: 36728303
Drug: Low-dose ICG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ICG (0.05 mg)
Trial: 36728303
Drug: Standard-dose ICG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ICG (2.5 mg)
Trial: 36728653
Drug: Varenicline solution
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline solution nasal spray (VNS) 0.03 mg
Trial: 36728874
Drug: Biweekly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly intravitreal aflibercept injections (IAI) 2 mg
Trial: 36728974
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily physical activity (PA)
Trial: 36729084
Drug: As-needed (PRN)
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As-needed (PRN) ranibizumab therapy
Trial: 36729422
Drug: SB2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 therapy for naïve CD patients
Trial: 36729422
Drug: SB2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 therapy for switched CD patients
Trial: 36729422
Drug: SB2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 therapy for all groups
Trial: 36729422
Drug: SB2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 therapy for naïve UC patients
Trial: 36729422
Drug: SB2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 therapy for switched UC patients
Trial: 36729494
Drug: Network-informed personalized
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Network-informed personalized treatment
Trial: 36729896
Drug: SIGN@L-A (serious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIGN@L-A (serious game with playful elements)
Trial: 36729896
Drug: SIGN@L-B (serious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIGN@L-B (serious game with only objectives and feedback)
Trial: 36730056
Drug: Tilavonemab 300
RxNorm normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilavonemab 300 mg
Trial: 36730056
Drug: Tilavonemab 1000
RxNorm normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilavonemab 1000 mg
Trial: 36730070
Drug: Glutamine administration
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine administration
Trial: 36730145
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose TPF (Docetaxel 75 mg/m2, Platinum 75 mg/m2, 5-Fluorouracil 750 mg/m2 IVCI x 5 days) followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) concurrent with radiation therapy of 70 Gy over 6.5-7 weeks.
Trial: 36730145
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose TPF followed by concurrent chemoradiation.
Trial: 36730289
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of AZA or 6-MP
Trial: 36730289
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of AZA or 6-MP
Trial: 36730749
Drug: Amphetamine Extended-Release
RxNorm normalized name: amphetamine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine Extended-Release Oral Suspension
Trial: 36731865
Drug: Early angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy initiated within 24 hours of admission.
Trial: 36732049
Drug: Efmarodocokin alfa
RxNorm normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efmarodocokin alfa (30-90 µg/kg doses given once every 2 weeks or monthly for 12 weeks)
Trial: 36732571
Drug: Premeal almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premeal almond load (20 g) before OGTT
Trial: 36732571
Drug: Premeal almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premeal almond load (20 g) before three major meals
Trial: 36732627
Drug: Serplulimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab (3 mg/kg) plus cisplatin (50 mg/m2)
Trial: 36732627
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin (50 mg/m2)
Trial: 36732628
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg plus nivolumab
Trial: 36732734
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home spirometry and pulse oximetry in the first three months, followed by once weekly measurements for two years.
Trial: 36732830
Drug: Reloading of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reloading of P2Y12 receptor inhibitors
Trial: 36733374
Drug: SDI-118, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDI-118, a novel procognitive SV2A modulator
Trial: 36733413
Drug: Pre-operative intravenous
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intravenous injection of butorphanol
Trial: 36733480
Drug: Polyvalent mechanical
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent mechanical bacterial lysate (PMBL) therapy
Trial: 39739195
Drug: Fezolinetant 30
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 30 mg
Trial: 39739195
Drug: Fezolinetant 45
RxNorm normalized name: fezolinetant 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 45 mg
Trial: 36734235
Drug: DAPT using
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT using cilostazol and either aspirin or clopidogrel (464 patients)
Trial: 36734235
Drug: SAPT using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAPT using aspirin or clopidogrel alone (461 patients)
Trial: 36734235
Drug: SAPT using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAPT using aspirin or clopidogrel
Trial: 36734294
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) combined with low-dose apatinib (500 mg daily)
Trial: 36734354
Drug: GLP-1 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (1.5 pmol/kg per minute) with 0.9% NaCl infusion (750 mL/h)
Trial: 36734354
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 0.9% NaCl infusion (750 mL/h)
Trial: 36734415
Drug: Allogeneic umbilical
RxNorm normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic umbilical cord blood (UCB) therapy, infused once intravenously
Trial: 36734848
Drug: Ferumoxytol-enhanced MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol-enhanced MRI before treatment with liposomal irinotecan (nal-IRI)
Trial: 36735117
Drug: Letrozole, everolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole, everolimus, and carotuximab (letrozole 2.5 mg PO daily, everolimus 10 mg PO daily, carotuximab 15 mg/kg IV every 2 weeks)
Trial: 36735635
Drug: Preoperative preparation-themed
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation-themed storybook (Elif Has Surgery) read by mother for 10 minutes
Trial: 36735745
Drug: GSK3772847 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3772847 (10 mg/kg) administered intravenously at Weeks 0, 4, and 8
Trial: 36735745
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously at Weeks 0, 4, and 8
Trial: 36735745
Drug: GSK3772847 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3772847 (10 mg/kg)
Trial: 36735896
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day
Trial: 36735931
Drug: Balanced Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Solution
Trial: 36735937
Drug: Pulsed Field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Field Ablation (PFA) system with variable-loop circular catheter, at least 12 applications per vein; adenosine/isoproterenol administered to confirm entrance block.
Trial: 36736112
Drug: Jitongning Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitongning Tablet (JTNT)
Trial: 36736209
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 0.6 μg/kg over 10 min, followed by continuous infusion of 0.5 μg/kg/h until 1 h before end of surgery)
Trial: 36736339
Drug: Increased adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increased adalimumab dose intervals to 40 mg every 3 weeks, further to every 4 weeks if in remission at week 24.
Trial: 36736339
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of adalimumab at 40 mg every 2 weeks.
Trial: 36736339
Drug: Increased adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increased adalimumab dose intervals (intervention group).
Trial: 36736339
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of adalimumab (control group).
Trial: 36737276
Drug: Maintenance oral
RxNorm normalized name: Cystex Urinary Health Maintenance oral soluti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance oral etoposide
Trial: 36737276
Drug: Maintenance oral
RxNorm normalized name: Cystex Urinary Health Maintenance oral soluti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance oral etoposide in platinum-refractory patients
Trial: 36737440
Drug: Azacytidine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacytidine treatment in MDS patients
Trial: 36737825
Drug: Ezetimibe tablet
RxNorm normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe tablet (10 mg)
Trial: 36737825
Drug: Ezetrol® (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetrol® (10 mg)
Trial: 36738100
Drug: ASP8062 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8062 60 mg
Trial: 36738333
Drug: TAK-164 (0.064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-164 (0.064 mg/kg)
Trial: 36738333
Drug: TAK-164 (0.032-0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-164 (0.032-0.25 mg/kg)
Trial: 36738756
Drug: Whole-breast irradiation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-breast irradiation (25 daily fractions of 50 Gy over 5 weeks with a supplemental boost of 10 Gy)
Trial: 36738756
Drug: APBI using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APBI using multicatheter brachytherapy (30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions over 5 days, or 50 Gy of pulsed-dose-rate brachytherapy over 5 days)
Trial: 36738762
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (subcutaneous golimumab 200 mg at week 0, subcutaneous golimumab 100 mg at weeks 2, 6, and 10, intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks for 32 weeks)
Trial: 36738762
Drug: Golimumab monotherapy
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab monotherapy (subcutaneous golimumab 200 mg at week 0 followed by subcutaneous golimumab 100 mg at week 2 and every 4 weeks thereafter for 34 weeks)
Trial: 36738762
Drug: Guselkumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab monotherapy (intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks thereafter for 32 weeks)
Trial: 36738762
Drug: Guselkumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab monotherapy